TheStreet upgraded shares of ProPhase Labs (NASDAQ:PRPH) from a d+ rating to a c- rating in a research report sent to investors on Wednesday.

ProPhase Labs stock opened at $2.99 on Wednesday. ProPhase Labs has a 1 year low of $2.03 and a 1 year high of $6.64. The company has a market capitalization of $34.28 million, a P/E ratio of 3.86 and a beta of 0.09.

ProPhase Labs (NASDAQ:PRPH) last released its earnings results on Monday, August 20th. The company reported ($0.02) earnings per share (EPS) for the quarter. ProPhase Labs had a negative net margin of 8.88% and a negative return on equity of 3.81%. The company had revenue of $3.19 million during the quarter.

An institutional investor recently raised its position in ProPhase Labs stock. Renaissance Technologies LLC boosted its stake in ProPhase Labs Inc (NASDAQ:PRPH) by 20.0% in the second quarter, according to the company in its most recent disclosure with the SEC. The firm owned 188,699 shares of the company’s stock after purchasing an additional 31,499 shares during the quarter. Renaissance Technologies LLC owned about 1.64% of ProPhase Labs worth $613,000 as of its most recent filing with the SEC. 4.30% of the stock is owned by institutional investors.

ProPhase Labs Company Profile

ProPhase Labs, Inc engages in the research, development, manufacture, distribution, marketing, and sale of over-the-counter(OTC) consumer healthcare products, dietary supplements, and other remedies in the United States. The company offers TK Supplements product line include Legendz XL for sexual health; Triple Edge XL, an energy booster and testosterone support; and Super ProstaFlow+ for prostate and urinary health.

Read More: What are defining characteristics of a correction?

Receive News & Ratings for ProPhase Labs Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ProPhase Labs and related companies with MarketBeat.com's FREE daily email newsletter.